iShares 3 7 Year Treasury Bond ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.56 (market cap $16.72B), while Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 9.6× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| IEI | NUVB | |
|---|---|---|
Market Cap | $16.72B | $1.74B |
Volume | 3,963,319 | 9,289,619 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $9.54 |
52-Week Low | $113.17 | $3.41 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
IEI is trading at $113.38 with minimal daily movement (+0.04%). The technical picture shows strong bearish momentum across moving averages and oscillators, with key indicators like the ADX signaling strong downward trends. Recent bond market volatility and rising Treasury yields create a challenging environment for fixed-income related investments. The company has maintained consistent dividend payments, with recent distributions of $0.37-$0.38 per share.
The outlook remains cautious given the bearish technical signals and broader bond market pressures. While dividend consistency provides some stability, the lack of available fundamental metrics and negative technical momentum suggests limited near-term upside potential. Investors should monitor Treasury yield developments and company financial disclosures for clearer directional signals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →